| 2 Brilliant Stocks to Buy With $200 and Hold for 5 Years |
While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more. |
fool.com |
2025-05-14 08:51:00 |
Czytaj oryginał (ang.) |
| Exact Sciences Earns 2025 Great Place To Work® Certification™ |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences' culture, work environment, and le. |
businesswire.com |
2025-05-12 14:00:00 |
Czytaj oryginał (ang.) |
| Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling |
Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue decline, the market response was positive due to promising growth projections and the launch of Cologuard Plus, a next-gen colon cancer screening test. Competition and high market cap valuation pose challenges, but Exact's first-mover advantage and new product launches offer potential for continued revenue growth. |
seekingalpha.com |
2025-05-02 16:52:21 |
Czytaj oryginał (ang.) |
| Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance |
Exact Sciences Corp. EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents. |
benzinga.com |
2025-05-02 13:18:11 |
Czytaj oryginał (ang.) |
| EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised |
Exact Sciences ends the first quarter of 2025 on a solid note. |
zacks.com |
2025-05-02 12:30:36 |
Czytaj oryginał (ang.) |
| Exact Sciences to Participate in May Investor Conference |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.co. |
businesswire.com |
2025-05-02 10:00:00 |
Czytaj oryginał (ang.) |
| Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript |
Exact Sciences Corporation. (NASDAQ:EXAS ) Q1 2025 Earnings Conference Call May 1, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Brian Baranick - General Manager, Precision Oncology Conference Call Participants Tycho Peterson - Jefferies Catherine Schulte - Baird Brandon Couillard - Wells Fargo Colleen Babington - Wolfe Research Patrick Donnelly - Citi Michael Ryskin - Bank of America Vijay Kumar - Evercore ISI Puneet Souda - Leerink Partners Subu Nambi - Guggenheim Andrew Brackmann - William Blair Luke Sergott - Barclays. |
seekingalpha.com |
2025-05-02 00:47:03 |
Czytaj oryginał (ang.) |
| Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates |
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.50 per share a year ago. |
zacks.com |
2025-05-01 22:40:44 |
Czytaj oryginał (ang.) |
| Exact Sciences Announces First-Quarter 2025 Results |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024. “Our strong first quarter results pave the way for 2025 to mark our most transformative year yet,” said Kevin Conroy, chairman and CEO. “The Exact Sciences team just launched two innovative tests: Cologua. |
businesswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar |
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
zacks.com |
2025-04-30 13:50:39 |
Czytaj oryginał (ang.) |
| Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release |
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-24 15:09:14 |
Czytaj oryginał (ang.) |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now |
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. |
zacks.com |
2025-04-23 13:55:52 |
Czytaj oryginał (ang.) |
| Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Oncodetect™—a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their healthcare providers with the insights needed to make more informed decisions throughout the treatment process, advancing the field of MRD testing. The Oncodetect test delivers clear "De. |
businesswire.com |
2025-04-22 10:00:00 |
Czytaj oryginał (ang.) |
| Tap Into the Silver Economy Boom With These Aging Demographics Stocks |
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health. |
zacks.com |
2025-04-14 20:00:39 |
Czytaj oryginał (ang.) |
| JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, “Genomic Assays for Breast Cancer in Diverse Populations: Prognostic and Predictive Insights,” affirms that the Oncotype DX test provides accurate and reliable information t. |
businesswire.com |
2025-04-14 10:00:00 |
Czytaj oryginał (ang.) |
| Exact Sciences Schedules First Quarter 2025 Earnings Call |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursd. |
businesswire.com |
2025-04-01 10:00:00 |
Czytaj oryginał (ang.) |
| Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening. |
businesswire.com |
2025-03-31 10:00:00 |
Czytaj oryginał (ang.) |
| Should You Retain Exact Sciences Stock in Your Portfolio Now? |
EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry. |
zacks.com |
2025-03-27 12:10:29 |
Czytaj oryginał (ang.) |
| Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time |
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time |
seekingalpha.com |
2025-03-17 13:52:59 |
Czytaj oryginał (ang.) |
| New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare Efficiency |
BAAR, Switzerland--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score® test at the 19th St. Gallen International Breast Cancer Conference in Vienna, Austria. A UK study1 explored the benefits of shifting the testing point to the pre-surgery setting by utilizing Oncotype DX on breast cancer core biopsy samples instead of surgical speci. |
businesswire.com |
2025-03-12 07:00:00 |
Czytaj oryginał (ang.) |
| Exact Sciences to Participate in J.P. Morgan Healthcare Conference |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San Francisco Presentation followed by Q&A on Monday, January 13, 2025 at 1:30 p.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences. |
businesswire.com |
2025-01-02 08:00:00 |
Czytaj oryginał (ang.) |
| AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates |
ALEXANDRIA, Va., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA) is proud to announce a new project, made possible through a grant from Exact Sciences, that aims to improve colorectal cancer screening rates.Physician associates/physician assistants (PAs) are often one of the first healthcare providers a patient sees, and thus are uniquely positioned to discuss screenings early on with patients.AAPA Chief Medical Officer Jennifer M. Orozco-Kolb, DMSc, PA-C, DFAAPA, said PAs play an important role in educating and encouraging patients to complete colorectal cancer screenings.“The 5-year survival rate for a patient who is diagnosed with colorectal cancer in the early stages is upward of 91%,” Orozco-Kolb said. “When a patient is diagnosed at a later stage, that survival rate drops to almost 14%. Screening through either at home DNA stool testing or traditional colonoscopy procedures should be considered when having conversations with patients about what works best for them.”The project consists of three phases. The first phase, which is underway, will feature focus group meetings with four federally qualified health centers (FQHCs) in Wisconsin and Arizona that previously received Exact Sciences funding to complete projects that improved colorectal cancer screening rates. These FQHCs were selected because they often serve underserved or uninsured patients who are less likely to access and complete colorectal cancer screenings.These focus group meetings are expected to be completed by February 2025, when the second phase of the project will begin. This phase involves taking lessons learned and best practices gathered during the focus groups and creating an innovative toolkit that can be widely used by providers across the country to improve their own colorectal cancer screening rates.The third phase will consist of taking the newly developed toolkit and implementing changes at select clinics across the country to measure outcomes.In 2024, the American Cancer Society ranked colorectal cancer as the third deadliest form of cancer in men, and fourth deadliest cancer in women. It's estimated that more than 152,000 people nationwide will be diagnosed with colorectal cancer this year.### Media Contacts: AAPA: Josh Birch, 443.614.5896 About the American Academy of Physician Associates (AAPA) AAPA is the national membership organization for all physician associates/physician assistants (PAs). PAs are licensed clinicians who practice medicine in every specialty and setting. Trusted, rigorously educated and trained healthcare professionals, PAs are dedicated to expanding access to care and transforming health and wellness through patient-centered, team-based medical practice. Learn more about the profession at aapa.org and engage through Facebook, LinkedIn, Instagram, and Twitter. |
globenewswire.com |
2024-12-09 12:01:00 |
Czytaj oryginał (ang.) |
| Exact Sciences Corporation (EXAS) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript) |
Exact Sciences Corporation (NASDAQ:EXAS ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 7:30 AM ET Company Participants Kevin Conroy - CEO Aaron Bloomer - CFO Conference Call Participants Vijay Kumar - Evercore Vijay Kumar Great. Thanks everyone for joining us this morning. |
seekingalpha.com |
2024-12-04 13:06:02 |
Czytaj oryginał (ang.) |
| Exact Sciences Corporation (EXAS) Citi's 2024 Global Healthcare Conference (Transcript) |
Exact Sciences Corporation (NASDAQ:EXAS ) Citi's 2024 Global Healthcare Conference December 3, 2024 8:45 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - EVP, Finance Conference Call Participants Patrick Donnelly - Citi Patrick Donnelly Thanks, everybody, for joining us here at the conference. Happy to have Kevin Conroy and Aaron Bloomer from Exact Sciences with us here today. |
seekingalpha.com |
2024-12-03 14:02:08 |
Czytaj oryginał (ang.) |
| Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has teamed up with multi-platinum, Grammy award-winning artist Lil Jon on the “Get Low #2” campaign to increase screening for colon cancer, the nation's #2 cancer-related killer.2 The partnership also highlights the Cologuard® test as an effective, non-invasive tool to help improve screening rates for adults 45 and older who are eligible. The stool-based Cologuard test overcomes co. |
businesswire.com |
2024-12-02 11:30:00 |
Czytaj oryginał (ang.) |
| Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED) |
Editor's note: The headline of this story was updated to correct an error related to the reported day of the week. |
benzinga.com |
2024-11-26 15:24:27 |
Czytaj oryginał (ang.) |
| Why Is Exact Sciences Stock Trading Higher On Monday? |
On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule. |
benzinga.com |
2024-11-26 14:21:15 |
Czytaj oryginał (ang.) |
| Exact Sciences to Participate in December Investor Conferences |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Citi Global Healthcare Conference, Miami Fireside chat on Tuesday, December 3, 2024 at 8:45 a.m. ET Evercore HealthCONx Conference, Miami Fireside chat on Wednesday, December 4, 2024 at 7:30 a.m. ET The webcasts can be accessed in the. |
businesswire.com |
2024-11-26 08:00:00 |
Czytaj oryginał (ang.) |
| Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024 |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas. “Exact Sciences is committed to improving breast cancer care by providing actionable insights that support informed treatment decisions and help achieve the best outcomes fo. |
businesswire.com |
2024-11-25 19:35:00 |
Czytaj oryginał (ang.) |
| Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript) |
Exact Sciences Corporation (NASDAQ:EXAS ) Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET Company Participants Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson Thank you both. Kevin, while you're walking up to the podium there, maybe you can talk a little bit about your recent purchase. |
seekingalpha.com |
2024-11-19 18:07:08 |
Czytaj oryginał (ang.) |
| EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test |
Exact Sciences presents new positive evidence backing the development of an MCED test. |
zacks.com |
2024-11-18 10:10:21 |
Czytaj oryginał (ang.) |
| Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy |
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening m. |
businesswire.com |
2024-11-13 15:00:00 |
Czytaj oryginał (ang.) |
| Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap. |
This article updates the investment merits of Exact Sciences following its disappointing Q3, 2024 earnings. Recent approval of an improved version of its lead product will not show up in revenues for a year or more. Despite its long history of losses, the company has comfortable liquidity cushions and will not need to raise cash to continue its normal operations. |
seekingalpha.com |
2024-11-10 13:39:29 |
Czytaj oryginał (ang.) |
| Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount |
Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook. |
investopedia.com |
2024-11-06 14:36:05 |
Czytaj oryginał (ang.) |
| Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point |
On Tuesday, Exact Sciences Corp. EXAS reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20. |
benzinga.com |
2024-11-06 12:13:21 |
Czytaj oryginał (ang.) |
| Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut |
EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion. |
zacks.com |
2024-11-06 10:55:30 |
Czytaj oryginał (ang.) |
| Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session |
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday. |
benzinga.com |
2024-11-06 09:58:45 |
Czytaj oryginał (ang.) |
| Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Transcript |
Exact Sciences Corporation (NASDAQ:EXAS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Erik Holznecht - Director, Investor Relations Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Tycho Peterson - Jefferies Andrew Brackman - William Blair Doug Schenkel - Wolfe Research Dan Brennan - Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Dan Arias - Stifel Jack Meehan - Nephron Research Patrick Donnelly - Citi Dan Leonard - UBS Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Andrew Cooper - Raymond James Mark Massaro - BTIG Operator Hello. At this time, I would like to welcome everyone to the Exact Sciences Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-05 23:06:46 |
Czytaj oryginał (ang.) |
| Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook |
Exact Sciences stock fell sharply Tuesday after the company cut its full-year outlook and posted weaker-than-expected results. The post Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook appeared first on Investor's Business Daily. |
investors.com |
2024-11-05 22:42:39 |
Czytaj oryginał (ang.) |
| Exact Sciences (EXAS) Reports Q3 Loss, Lags Revenue Estimates |
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to break-even earnings per share a year ago. |
zacks.com |
2024-11-05 20:30:18 |
Czytaj oryginał (ang.) |